An unusual flare of anti-synthetase syndrome during concurrent trastuzumab therapy given for recurrent breast cancer.
Anti-synthetase syndrome (ASS) is an autoimmune connective tissue disease (CTD) defined by the presence of anti-aminoacyl tRNA synthetase (anti-ARS) autoantibodies. Recently, this condition has been recognized as a discrete entity within the spectrum of what has been traditionally known as polymyositis and dermatomyositis. Currently, there are eight identified anti-ARS autoantibodies, with anti-Jo1 being the most freguently observed. The characteristic clinical features of ASS include myositis, inflammatory arthropathy, skin lesions, constitutional symptoms including fever, and interstitial lung disease (ILD) (1). ASS is a spectrum disorder where patients sometimes present with limited manifestations such as ILD and fever. Myocardial involvement is rare, and unlike other dermatomyositis serological phenotypes (particularly anti-TIF1 or anti-NXP2 subsets), cancer-associated myositis in ASS is less common (1). Here we present the case of a patient with relapsing ASS that may have been triggered by the concurrent use of monoclonal antibody trastuzumab therapy administered alongside chemotherapy for recurrent breast cancer.
A 52-year-old Afro-Caribbean female with a three-year history of anti-Jo1-associated ASS presented with proximal weakness, elevated creatine kinase levels (4470 IU/L), and non-specific interstitial pneumonia (NSIP) and organizing pneumonia (OP) patterns on performing high-resolution computed tomography (HRCT) imaging. Her past medical history included invasive ductal carcinoma of the right breast that was diagnosed and fully treated six years prior to the presentation of ASS. Myositis and ILD responded well to reducing doses of oral glucocorticoids and mycophenolate mofetil; she showed significant clinical improvement, normalization of creatine kinase levels, and improvement in lung physiology. Seven years after her original breast cancer and one year after ASS remission, she developed recurrent right-breast invasive ductal carcinoma. She remained on low-dose glucocorticoids, and mycophenolate mofetil was stopped prior to undergoing right-sided mastectomy. Following surgery, she was treated with six cycles of cyclophosphamide (600 mg/[m.sup.2]) and docetaxel (75 mg/[m.sup.2]). Following the initial chemotherapy regimen, she remained stable with no flare of CTD features. During her chemotherapy regimen, she underwent adjuvant therapy with three weekly subcutaneous trastuzumab injections and hormonal treatment with letrozole. She was admitted with worsening breathlessness, swinging fever and leukopenia following the sixth course of chemotherapy and sixth dose of trastuzumab. Herclinical examination and plain chest radiographs demonstrated bilateral chest consolidation with pleural effusions. She was initially treated for presumed neutropenic sepsis with intravenous antibiotics and granulocyte colony-stimulating factor. Despite these treatments, there was further deterioration in her clinical and physiological respiratory function (forced vital capacity was 69% of the predicted level; transfer factor for carbon monoxide was 33% of the predicted level with desaturation on exertion). She also described recurrence of proximal lower limb myalgia accompanied by an increase in creatine kinase levels to 3390 IU/L and troponin-T levels to 112 ng/L (normal level: <14 ng/L). HRCT imaging demonstrated a marked peri-bronchocentric patchy consolidation and subpleural reticulation, consistent with NSIP/OP patterns (Figure 1). The combined features, which included swinging fever, ILD, myositis, and possible subclinical myocarditis, represented a flare of ASS. She responded well to IV methylprednisolone; an increased dose of oral glucocorticoids and mycophenolate mofetil was restarted. Echocardiography along with a cardiac MRI scan demonstrated long-axis LV systolic impairment and regional hypokinesia but not myocardial edema, although the MRI scan was performed after steroids were started, so this may have masked some features. There was a marked overall clinical improvement alongside the improvement in lung physiology and normalization of creatine kinase levels (Figure 2). The patient remains stable on immunomodulatory treatment along with letrozole monotherapy for breast cancer.
Written informed consent was obtained from the patient.
Trastuzumab is a monoclonal antibody to the human epidermal growth factor 2 (HER-2) receptor. It is known to significantly reduce the rate of breast cancer recurrence, but it has been linked to cardiac toxicity, particularly when used in conjunction with anthracycline chemotherapy (not in our patient) (2). Our patient was treated with 14cycles of trastuzumab therapy as part of her treatment regimen when she first developed breast cancer six years prior to presentation; however, it was stopped following a small asymptomatic drop in her left ventricular ejection fraction from 63% to 50%. Her cardiac function had recovered prior to commencing treatment for recurrent breast cancer, so the decision was made to include trastuzumab as part of her treatment regimen, along with performing repeat echocardiography at three-month intervals to monitor deterioration. Trastuzumab has also been linked to precipitating ILD (3). This can have various acute manifestations including infusion reactions, acute lung injury, or pneumonitis among patients who have recently started taking the medication. There have also been reports of delayed onset of OP in patients taking trastuzumab for prolonged periods (3-5).
We believe that this is the first recorded case of a flare of ASS temporally linked to the commencement of trastuzumab therapy, with marked deterioration of ILD, swinging fever, myositis, and possible myocardial involvement. While it is possible that the flare of the disease can be partially explained by the patient having stopped taking mycophenolate mofetil at the time of commencing chemotherapy, our case is noteworthy as the patient received cyclophosphamide pulses as part of the breast cancer therapy, which is a recognized treatment option for ASS-associated ILD and/or myositis and as it would be extremely unusual for the disease to flare so soon after receiving such significant immunosuppression. Other cases of lung and cardiac disease linked to trastuzumab generally occurred earlier (within 6 weeks of the introduction of the drug) than what is reported in the present case; however, it is possible that the concurrent use of cyclophosphamide resulted in delayed presentation. Nonetheless, this patient flared shortly after the introduction of trastuzumab and improved on the cessation of the monoclonal antibody along with additional immunomodulatory therapy. This case highlights a potential risk of HER-2 therapy for breast cancer in patients with known overlap between CTD and ILD. It is known that epidermal growth factor receptors are widely expressed in most human tissues and have an important function in cell signaling with roles in coordinating myoblast differentiation and innate immune responses (6-7). We hypothesize that the loss of regulation within these pathways contributed to the disease flare reported in our patient.
Informed Consent: Written informed consent was obtained from the patient who participated in this study.
Peer-review: Externally peer-reviewed.
Author Contributions: Concept - T.R., HA, H.G.; Design -T.R., V.M., M.R., N.M., HA, H.G.; Supervision - T.R., H.G.; Data Collection and/or Processing - T.R., V.M., M.R., N.M., H.A., H.G.; Analysis and/or Interpretation - T.R., V.M., M.R., N.M., H.A., H.G.; Literature Search - T.R., H.G.; Writing Manuscript - T.R., V.M., M.R., N.M., H.A., H.G.; Critical Review - T.R., H.G.
Conflict of Interest: No conflict of interest was declared by the authors.
Financial Disclosure: The authors declares that this study has received no financial support.
(1.) Gunawardena H. The Clinical Features of Myositis-Associated Autoantibodies: a Review. Clin Rev Allergy Immunol 2017; 52:45-57. [CrossRef]
(2.) Ewer MS, Gibbs HR, Swafford J, Benjamin RS. Cardiotoxicity in patients receiving trastuzumab (Herceptin): primary toxicity, synergistic or seguential stress, or surveillance artifact? Semin Oncol 1999;26:96-01.
(3.) Vahid B, Marik P. Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors. Chest 2008; 133:528-38. [CrossRef]
(4.) Taus-Garcia A, Sanchez-Font A, Servitja-Tormo S, Pijuan L, Maigues-Llacer JM, Curull V. Organizing Pneumonia Associated with the Use of Trastuzumab. Archivos de Bronconeumologia 2010; 46:442-44. [CrossRef]
(5.) Vahid B, Mehrotra A. Trastuzumab (Herceptin) - associated lung injury. Respirology 2006; 11: 655-58. [CrossRef]
(6.) Leroy MC, Perroud J, Darbellay B, Bernheim L, Konig S. Epidermal Growth Factor Receptor Down-Regulation Triggers Human Myoblast Differentiation. PLoS One 2013; 8: e71770. [CrossRef]
(7.) Burgel P-R, Nadel J A. Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases. Eur Respir J 2008; 32:1068-1081. [CrossRef]
Timothy D. Reynolds (1), Vivek Mohan (2), Matthew Roy (3), Nathan Manghat (4), Huzaifa Adamali (5), Harsha Gunawardena (6)
(1) Department of Rheumatology and Medical Education, North Bristol NHS Trust, Bristol, UK
(2) Department of Oncology, Bristol Cancer Institute, Bristol, UK
(3) Department of Rheumatology, Bristol Royal Infirmary, Bristol, UK
(4) Department of Radiology, Bristol Royal Infirmary and Bristol Heart Institute, Bristol, UK
(5) Bristol Interstitial Lung Disease Service, Southmead Hospital, Bristol, UK
(6) Department of Rheumatology and Bristol Interstitial Lung Disease Service, Southmead Hospital, Bristol, UK
Address for Correspondence: Timothy D. Reynolds, Department of Rheumatology and Medical Education, North Bristol NHSTrust, Bristol, UK
Submitted: 13 March 2017
Accepted: 11 May 2017
Available Online Date: 25 October 2017
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Case Report|
|Author:||Reynolds, Timothy D.; Mohan, Vivek; Roy, Matthew; Manghat, Nathan; Adamali, Huzaifa; Gunawardena, Ha|
|Publication:||European Journal of Rheumatology|
|Date:||Dec 1, 2017|
|Previous Article:||Targeting IL-17 in psoriatic arthritis.|
|Next Article:||Catastrophic antiphospholipid syndrome: A case with unusual findings revealed in autopsy and a brief literature update.|